Table 1.

Correlation between TET1 gene expression and clinicopathological and molecular factors in colorectal cancer

Characteristics	Total n = 22	TET1 expression		P‐value
		Downregulated n = 11	Upregulated/equivalent n = 11
Age at surgery
Mean ± SD (years)	65.3 ± 13.0	62.5 ± 13.4	67.8 ± 12.7	0.363
Range (years)	39–88	39–81	50–88
Sex, n (%)
Male	12 (54.5)	5 (45.5)	7 (63.6)	0.392
Female	10 (45.5)	6 (54.5)	4 (36.4)
Site of tumor, n (%)
Proximal	8 (38.1)	6 (60.0)	2 (18.2)	0.049
Distal	13 (61.9)	4 (40.0)	9 (81.8)
Dukes grade, n (%)
A, B	11 (52.4)	6 (60.0)	5 (45.5)	0.505
C, D	10 (47.6)	4 (40.0)	6 (54.5)
Tumor grade, n (%)a
Well diff	4 (19.0)	2 (20.0)	2 (18.2)	0.916
Moderately diff and mucinous	17 (81.0)	8 (80.0)	9 (81.8)
KRAS exon 2, n (%)
Wild‐type	15 (68.2)	8 (72.7)	7 (63.6)	0.647
Mutant	7 (31.8)	3 (27.3)	4 (36.4)
BRAF exon 15, n (%)
Wild‐type	20 (90.9)	10 (90.9)	10 (90.9)	1
Mutant	2 (9.1)	1 (9.1)	1 (9.1)
TET2 gene expression, n (%)
Downregulated	2 (14.3)	2 (28.6)	0 (0.0)	0.127
Upregulated or equivalent	12 (85.7)	5 (71.4)	7 (100)
TET3 gene expression, n (%)
Downregulated	10 (45.5)	9 (81.8)	1 (9.1)	0.0006
Upregulated or equivalent	12 (54.5)	2 (18.2)	10 (90.9)
DNMT1 gene expression, n (%)
Downregulated	8 (36.4)	8 (72.7)	0 (0.0)	0.0004
Upregulated or equivalent	14 (63.6)	3 (27.3)	11 (100)
DNMT3A gene expression, n (%)
Downregulated	7 (31.8)	6 (54.5)	1 (9.1)	0.022
Upregulated or equivalent	15 (68.2)	5 (45.5)	10 (90.9)
DNMT3B gene expression, n (%)
Downregulated	10 (45.5)	6 (54.5)	4 (36.4)	0.392
Upregulated or equivalent	12 (54.5)	5 (45.5)	7 (63.6)
5‐hmC level, n (%)
Reduced	16 (72.7)	8 (72.7)	8 (72.7)	1
Equivalent	6 (27.3)	3 (27.3)	3 (27.3)
5‐mC level, n (%)
Reduced or equivalent	19 (86.4)	10 (90.9)	9 (81.8)	0.534
Increased	3 (13.6)	1 (9.1)	2 (18.2)

^aTumor grade: diff, differentiated. Significant P‐values (< 0.05) are shown in bold.